F S&P 500
5,544.75 +7.75 (+0.14%) F Dow Jones
39,528.00 +2.00 (+0.01%) F Nasdaq
20,018.25 +46.00 (+0.23%) E-mini Russell 2000 Index Futur
2,045.40 +0.50 (+0.02%) Petróleo
81.37 +0.54 (+0.67%) Oro
2,327.10 -3.70 (-0.16%)
Defence Therapeutics Inc. (DTCFF)
Defence Therapeutics Inc.
1680 – 200 Burrard Street
Vancouver, BC V6C 3L6
Canada
514 947 2272
https://defencetherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo:
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Sebastien Plouffe | CEO, President & Director | 82.36k | N/D | 1972 |
| Mr. Patrick Joseph Meagher C.A., CPA, CA, CPA | CFO & Director | 58.2k | N/D | 1986 |
| Dr. Moutih Rafei Ph.D. | Chief Scientific Officer & Director | 9.15k | N/D | 1982 |
| Dr. Simon Beaudoin | Chief Technical Science Officer | N/D | N/D | 1985 |
| Ms. Carrie Cesarone | Corporate Secretary | N/D | N/D | 1965 |
Descripción
Defence Therapeutics Inc. engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de Defence Therapeutics Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
